OTHER INFORMATION.
+Added: Rule 10b5-1 Trading Plans
+Added: On August 31, 2023 , Christine Chung , Senior Vice President , China Operations of the Company, terminated a Rule 10b5-1 trading plan, which was previously adopted on March 7, 2023 and intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: The plan provided for the potential sale of up to 125,000 shares of common stock held by Ms.
+Added: Prior to its termination, Ms.
+Added: Chung sold 12,500 shares under the plan.
+Added: On July 12, 2023 , Mark Eisner , then Chief Medical Officer of the Company, terminated a Rule 10b5-1 trading plan, which was previously adopted on March 2, 2023 and intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: The plan provided for the potential sale of up to 107,260 shares of common stock held by Mr.
+Added: Prior to its termination, Mr.
+Added: Eisner sold 0 shares under the plan.
+Added: On August 31, 2023 , Juan Graham , Chief Financial Officer of the Company, terminated a Rule 10b5-1 trading plan, which was previously adopted on August 26, 2022 and intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: The plan provided for the potential sale of up to 29,911 shares of common stock held by Mr.
+Added: Prior to its termination, Mr.
+Added: Graham sold 7,929 shares under the plan.
+Added: On September 22, 2023 , Jeffrey Henderson , a member of the Company’s Board of Directors , terminated a Rule 10b5-1 trading plan, which was previously adopted on March 3, 2023 and intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: The plan provided for the potential sale of up to 20,000 shares of common stock held by Mr.
+Added: Prior to its termination, Mr.
+Added: Henderson sold 6,000 shares under the plan.
Incorporation By Reference
5 unchanged sentences
and AstraZeneca AB, dated as of October 20, 2014.
−Removed: Amendment No.
−Removed: 1 to Commercial Supply Agreement (Roxadustat) by and between FibroGen, Inc.
−Removed: and its Affiliates and Catalent Pharma Solutions, LLC dated as of January 1, 2023.
Offer Letter, dated July 23, 2023, between FibroGen, Inc.
2 unchanged sentences
and Enrique Conterno.
−Removed: Amended and Restated Exclusive License Agreement by and among FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd., and Eluminex Biosciences Suzhou) Limited, dated April 19, 2023.
−Removed: Financing Agreement by and among FibroGen, Inc., certain of its subsidiaries, NHTV Fairview Holding LLC, NHTV II Fairview Holding LLC, MSTV Fund II Employees Fairview Holding LLC, and Wilmington Trust, National Association, dated as of April 29, 2023.
−Removed: Evaluation Agreement by and between FibroGen, Inc.
−Removed: and Fortis Therapeutics, Inc., dated May 5, 2023.
−Removed: Option Agreement and Plan of Merger by and among FibroGen, Inc., Fortis Therapeutics, Inc., and Shareholder Representative Services LLC, dated as of May 5, 2023.
Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).
11 unchanged sentences
+ Indicates a management contract or compensatory plan.
−Removed: * Filed herewith
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
FibroGen, Inc.
−Removed: August 7, 2023
+Added: November 6, 2023
/s/ Thane Wettig
−Removed: Interim Chief Executive Officer
+Added: Chief Executive Officer
(Principal Executive Officer)
−Removed: August 7, 2023
+Added: November 6, 2023
/s/ Juan Graham
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.